This article is more than 5 years old. Information may no longer be current.
Multi-biomarker DAS effectively predicted radiographic progression in RA
A multi-biomarker disease activity score at baseline effectively predicted radiographic progression in patients with early rheumatoid arthritis, according to recent study results.
Researchers analyzed baseline disease activity score 28 based on erythrocyte sedimentation rate (DAS28-ESR), DAS28 based on C-reactive protein (DAS28-CRP), CRP, multi-biomarker disease activity (MBDA) scores and DAS28-ESR at 3 months for 235 patients with early rheumatoid arthritis (eRA; duration <1 year) from a Swedish clinical trial. Increases of more than 5 points in Sharp-van der Heijde score during 1 year were used to define radiographic progression (RP).
Adjusted univariate and multivariate logistic regression were used to evaluate associations between the MBDA and 1-year RP, using the Vectra DA (Crescendo Bioscience), multi-biomarker blood test.
Five patients had low MBDA scores (<30) at baseline, while 29 had moderate scores (30-44). No patients with low MBDA scores and one with a moderate score experienced RP during 1 year; 20.9% of patients with high MBDA score (>44; n=201), however, met RP (P=.021).
“Among patients with low CRP, moderate CRP, moderate DAS28-CRP or moderate DAS28-ESR at baseline, progression occurred in 14%, 15%, 14% and 15% respectively,” the researchers reported.
RP as a continuous (OR=1; 95% CI, 1.02-1.08) or dichotomized (high/low) variable (OR=3.86; 95% CI, 1.04-14.26) was independently predicted by MBDA score.
“In DMARD-naive patients with eRA, low/moderate MBDA score at baseline was shown to be associated with a very low risk of RP after 1 year,” the researchers concluded.
“Our study demonstrates that Vectra DA provides highly relevant clinical information in patients with newly diagnosed rheumatoid arthritis,” researcherRonald F. van Vollenhoven, MD, PhD, department of medicine, Karolinska University Hospital, Stockholm, said in a press release. “With this test taken before antirheumatic therapies are started, the clinician will have more knowledge about the patient’s prognosis to help inform decisions regarding treatment, an important step toward personalized medicine in the treatment of this important musculoskeletal disease.”
Disclosure: See the study for a full list of relevant financial disclosures.